Home › Funds › DDFG, Inc › ARWR
DDFG, Inc position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
DDFG, Inc reported holding 10,728 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$702K, representing 0.14% of its reported portfolio and ranking #48 among its reported holdings. DDFG, Inc has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How DDFG, Inc's ARWR position evolved
DDFG, Inc first disclosed a stake in ARWR in Q3 2023 at 14,728 shares (US$396K). The position peaked in Q4 2025 at 14,728 shares, worth US$978K. Across 13 filings, DDFG, Inc increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 10,728 shares valued at US$702K. Notable position changes include a 27% trim in Q1 2026 (shares rose 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 14.73K | $395.74K | New |
| Q4 2023 | 14.73K | $450.68K | Hold |
| Q1 2024 | 14.73K | $421.22K | Hold |
| Q2 2024 | 14.73K | $382.78K | Hold |
| Q3 2024 | 14.73K | $285.28K | Hold |
| Q4 2024 | 14.73K | $276.89K | Hold |
| Q1 2025 | 14.73K | $187.63K | Hold |
| Q2 2025 | 14.73K | $232.70K | Hold |
| Q3 2025 | 14.73K | $507.97K | Hold |
| Q4 2025 | 14.73K | $977.79K | Hold |
| Q1 2026 | 10.73K | $672.65K | Reduce |
| Q2 2026 | 10.73K | $874.44K | Hold |
| Q3 2026 | 10.73K | $702.15K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 53 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 1.72M sh · $139.83M · Q2 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
FAQ
How long has DDFG, Inc held ARWR?
DDFG, Inc has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DDFG, Inc's current position in ARWR?
As of Q3 2026, DDFG, Inc holds 10.73K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $702.15K, representing 0.14% of its reported portfolio and ranking #48.
Has DDFG, Inc been buying or selling ARWR?
In the latest 13F filing (Q3 2026), DDFG, Inc held unchanged its position in ARWR. The position peaked in Q4 2025 at 14.73K shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.